730PA pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis. (23rd October 2018) - Yu, K; Mantha, S; Tjan, C; Kaufmann, E; Brenner, R B; Lowery, M; Ku, G; Raj, N; Shcherba, M; Goldberg, Z; Li, J; Zervoudakis, A; et al.